The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested target is unambiguously human E2F transcription factor 1 (E2F1), not E2F2, E2F7, the lncRNA EMSLR, or a non-human similarly named protein. Its approved human gene is E2F1 (Ensembl ENSG00000101412), and the reported aliases RBAP-1/RBBP3 reflect its original identification as a retinoblastoma-protein-binding factor. The literature agrees with the supplied UniProt assignment to the E2F/DP family and with the listed winged-helix-like DNA-binding, E2F–DP heterodimerization, coiled-coil, and marked-box domains. Open Targets likewise identifies ENSG00000101412 as “E2F transcription factor 1.” (OpenTargets Search: -E2F1, zhou2023expandingrolesof pages 2-4)
E2F1 is not an enzyme or transporter. Its primary molecular function is to act in the nucleus as a sequence-specific, DP-dependent transcriptional activator. It converts mitogenic cyclin–CDK/pRB signaling into transcription of genes needed for G1/S progression, DNA synthesis, and replication. A second, well-supported function is as a transcription-independent chromatin-accessory factor at DNA lesions, where modified E2F1 recruits acetyltransferases, remodelers, and repair machinery. Excessive or deregulated E2F1 can instead engage ARF–MDM2–p53 and p53-independent apoptotic programs. Thus, E2F1’s biological output depends strongly on activation amplitude, modification state, cell type, and genomic context. (zhou2023expandingrolesof pages 2-4, zhou2023expandingrolesof pages 14-16, manickavinayaham2020thee2f1transcription pages 3-5)
| Annotation area | Best-supported conclusion | Key experimental evidence/model | Evidence strength / caveat |
|---|---|---|---|
| Identity and domains | Human E2F1 (UniProt Q01094; ENSG00000101412) is an activator-class E2F/DP-family transcription factor with a winged-helix-like DNA-binding domain, coiled-coil/marked-box DP-dimerization region, nuclear-localization signal, cyclin-A-binding region, and C-terminal transactivation/RB-binding function. | Recent family review and direct E2F1–DP1–RB structural work; DNA-contact geometry is partly inferred from homologous E2F4–DP2 structures. (OpenTargets Search: -E2F1, zhou2023expandingrolesof pages 2-4, saad2021structuraldeterminantsof pages 25-28, rubin2005structureofthe pages 1-2) | High for identity, family, and overall architecture; moderate for the complete DNA-bound structure because no full-length atomic E2F1 structure is available. |
| Nuclear transcription and G1/S | Nuclear E2F1–DP heterodimers activate genes required for G1/S entry, DNA synthesis, and replication; cited targets include CCNE, CDC6, and E2F-family genes. DP association increases sequence-specific DNA binding. | Functional synthesis and E2F1/DP1 integrative structural studies support promoter binding and transcriptional activation. (zhou2023expandingrolesof pages 2-4, saad2021highconformationalflexibility pages 8-11, saad2021highconformationalflexibility pages 11-13) | High for the canonical G1/S role; individual target occupancy and output remain cell- and context-dependent. |
| RB and CDK control | Hypophosphorylated pRB binds E2F1–DP and represses transactivation; RB phosphorylation releases E2F. Cyclin A–CDK2 phosphorylation of E2F/DP inhibits DNA binding later in S phase. | The RB C-terminal structure shows direct contacts with E2F1/DP1 marked-box domains. RB Ser788/Ser795 and Thr821/Thr826 phosphorylation disrupts contacts through direct and intramolecular mechanisms. (zhou2023expandingrolesof pages 2-4, rubin2005structureofthe pages 1-2) | High, supported by direct structure and biochemical regulation; distinct RB phosphorylation events act sequentially. |
| Apoptosis and RB–ARF–MDM2–p53 | Excess or deregulated E2F activity can induce ARF, which inhibits MDM2 and stabilizes p53, promoting arrest, senescence, or apoptosis. E2F1 can also activate p53-independent pro-apoptotic programs. | Pathway synthesis identifies ARF and targets including TP73, BIM, RASSF1, PPP1R13B, JMY, and MOAP1; ATM/NBS1 loss attenuates E2F1-induced p53 phosphorylation and apoptosis. (zhou2023expandingrolesof pages 14-16, zhou2023expandingrolesof pages 1-2) | High for pathway logic, but the outcome is context-dependent: E2F1 can support proliferation or cell death. |
| UV-lesion DNA repair | E2F1 has a transcription-independent nuclear role at UV-damaged chromatin. ATR-dependent Ser31 phosphorylation enables TopBP1 binding and lesion localization, followed by GCN5 recruitment, H3K9 acetylation, and improved loading of NER factors including XPA/XPC. | Human-cell localization, knockdown, and recruitment studies show that the DNA-binding and transactivation domains are dispensable for damage-site localization. (manickavinayaham2020thee2f1transcription pages 3-5, guo2011gcn5ande2f1 pages 2-2, putzer2013e2f1apoptosiscounterattacked pages 5-6) | High cellular mechanistic evidence; E2F1 is an accessory chromatin/repair factor rather than an enzyme that repairs DNA directly. |
| Double-strand-break repair | ATM/ATR-phosphorylated E2F1 cooperates with RB at DSBs and recruits p300/CBP, BRG1, and MRN-associated machinery, promoting chromatin acetylation, end resection, and homologous recombination; RAD51 and RPA recruitment or retention is also enhanced. | Human-cell damage-site assays and modification-deficient knock-in models support Ser31- and acetylation-dependent recruitment and repair. (zhou2023expandingrolesof pages 14-16, manickavinayaham2020thee2f1transcription pages 3-5, manickavinayaham2020thee2f1transcription pages 1-3, velezcruz2012e2f1andp53 pages 3-5) | High for damage-site localization and repair support; some physiological evidence comes from mouse knock-in models. |
| 2024 FBXW7–Ser403–calcineurin mechanism | E2F1 Ser403 phosphorylation creates an FBXW7-recognition determinant that promotes ubiquitination and proteasomal degradation; calcineurin-mediated dephosphorylation suppresses FBXW7 binding and stabilizes E2F1. | E2F1-S403A was more stable than wild type in HEK293T cycloheximide-chase assays. Calcineurin inhibition lowered E2F1 and suppressed HT29 xenograft growth, with significant tumor reduction from treatment day 12 and lower E2F1 after 21 days. (sato2024calcineurinmediateddephosphorylationstabilizes pages 11-12, sato2024calcineurinmediateddephosphorylationstabilizes pages 3-4) | Moderate-to-high preclinical evidence; exact effect sizes and sample sizes were unavailable, and systemic calcineurin inhibition is not E2F1-specific. |
| Cancer and translational status | E2F1 is an important output of dysregulated RB/CDK signaling and a candidate biomarker or therapeutic node, but it is not an established directly drugged clinical target. Indirect strategies include CDK-pathway modulation and alteration of E2F1 stability. | Cancer-cell and xenograft studies support pathway dependencies; the clinical-trial search found no relevant direct E2F1 intervention, while calcineurin/FBXW7 work remains preclinical. (OpenTargets Search: -E2F1, sato2024calcineurinmediateddephosphorylationstabilizes pages 11-12, sato2024calcineurinmediateddephosphorylationstabilizes pages 3-4) | Strong biological rationale but low clinical maturity; E2F1’s proliferative, apoptotic, and repair functions complicate safety and patient selection. |
Table: Compact evidence map for human E2F1 (UniProt Q01094), separating established molecular functions from newer preclinical mechanisms and translational limitations.
All mandatory checks passed:
The E2F1 polypeptide contains an N-terminal nuclear-localization region and cyclin-A interaction site, a conserved winged-helix-like DNA-binding domain, and coiled-coil/marked-box regions that associate with DP proteins. A roughly 60-residue C-terminal transactivation region engages transcriptional machinery and is inhibited by pRB binding. Direct crystallography of an E2F1–DP1–RB C-terminal complex shows that the E2F1 and DP1 coiled-coil/marked-box regions form an intertwined heterodimer and that both marked-box domains contact RB. (zhou2023expandingrolesof pages 2-4, saad2021structuraldeterminantsof pages 25-28, rubin2005structureofthe pages 1-2)
A complete full-length atomic structure of DNA-bound E2F1 is not available in the retrieved evidence. Detailed DNA-contact geometry is partly inferred from homologous E2F4–DP2 crystallography and integrated with direct E2F1–DP1 coiled-coil/marked-box structures, SAXS, and molecular dynamics. Therefore, the overall fold and recognition mechanism are strongly supported, but some residue-level descriptions remain homology-assisted rather than direct full-length E2F1 crystallography. (saad2021highconformationalflexibility pages 16-19, saad2021highconformationalflexibility pages 24-25)
E2F1 binds DNA efficiently as a heterodimer with DP1 or DP2. The E2F and DP DNA-binding domains recognize opposite parts of an E2F site, while their coiled-coil/marked-box regions stabilize heterodimerization. Canonical sites contain a CG-rich core; reported matrices include a symmetric CGCGC core and a broader TTTSSCGC-type sequence. Because these precise contacts derive partly from E2F4–DP2 and modeling, they should be interpreted as the canonical E2F/DP recognition mechanism rather than a uniquely measured E2F1-only consensus. (saad2021structuraldeterminantsof pages 25-28, saad2021highconformationalflexibility pages 11-13)
Integrative E2F1–DP1 analysis identified E2F1 Arg165–Arg166 and DP1 Arg167–Arg168 as modeled DNA-contact residues. The complex is conformationally flexible: its coiled-coil/marked-box module can flex by approximately 80° relative to the DNA-binding module. DP1 residues 105–113 form a flexible basic extension that stabilizes contacts beyond the core site; extending DNA on the DP1 side increased competition values to 1.27–1.30 relative to a 15-bp baseline, without strong adjacent-sequence preference. A SAXS-refined model fitted the experimental profile with χ² = 1.26. (saad2021highconformationalflexibility pages 8-11, saad2021highconformationalflexibility pages 11-13, saad2021highconformationalflexibility pages 16-19, saad2021highconformationalflexibility pages 24-25)
The best-established physiological role is activation of a coordinated proliferation program at the G1/S transition. Directly discussed targets include CCNE/cyclin E and CDC6, alongside E2F-family autoregulatory targets and broader groups involved in DNA synthesis, replication origins, checkpoint control, and later cell-cycle progression. E2F1 should therefore be annotated as a nuclear transcriptional regulator of cell-cycle commitment and replication capacity—not simply as a generic “oncogene.” (zhou2023expandingrolesof pages 2-4)
In quiescent or growth-restrained cells, hypophosphorylated pRB binds E2F1–DP and suppresses transactivation. Mitogenic signaling activates cyclin–CDK complexes, phosphorylates pRB, and releases active E2F, creating a feed-forward transcriptional program that drives G1/S entry. Later, cyclin A–CDK2 phosphorylation of E2F/DP inhibits DNA binding, helping terminate E2F activity during S phase. (zhou2023expandingrolesof pages 2-4, zhou2023expandingrolesof pages 1-2)
Direct structural work provides a molecular explanation for pRB release. Phosphorylation of pRB Ser788/Ser795 directly destabilizes one set of RB–E2F1–DP1 contacts; phosphorylation at Thr821/Thr826 promotes an intramolecular interaction between the RB C terminus and RB pocket, indirectly displacing remaining E2F contacts. This is stronger evidence than pathway correlation because it combines structure with biochemical perturbation. Rubin et al., Cell, December 2005, DOI: https://doi.org/10.1016/j.cell.2005.09.044. (rubin2005structureofthe pages 1-2)
E2F1 carries an N-terminal nuclear-localization signal and performs its canonical function on nuclear chromatin. Its localization is dynamic rather than uniformly promoter-bound: after DNA damage, ATM/ATR-dependent modification and TopBP1 binding concentrate E2F1 at UV lesions or double-strand breaks. Its DNA-binding and transactivation domains are dispensable for this damage-site localization, demonstrating that recruitment to lesions is mechanistically distinct from promoter recognition. (zhou2023expandingrolesof pages 2-4, manickavinayaham2020thee2f1transcription pages 3-5, manickavinayaham2020thee2f1transcription pages 1-3)
No evidence supports a primary extracellular, plasma-membrane, organellar-enzymatic, or secreted function. Reports of cytoplasmic regulatory interactions concern trafficking or stability and do not replace the nucleus as its principal functional compartment.
DNA damage activates ATM/ATR phosphorylation of human E2F1 at Ser31, a residue not conserved across all E2F proteins. Phospho-Ser31 binds the sixth BRCT domain of TopBP1, stabilizing E2F1 and recruiting it to damaged chromatin. At UV lesions, E2F1 recruits GCN5, promotes H3K9 acetylation and chromatin accessibility, and supports loading of nucleotide-excision-repair proteins including XPA and XPC. This role is transcription independent: UV-induced E2F1 stabilization can enhance repair without activating its apoptotic transcriptional program. (manickavinayaham2020thee2f1transcription pages 3-5, guo2011gcn5ande2f1 pages 2-2, putzer2013e2f1apoptosiscounterattacked pages 5-6, velezcruz2012e2f1andp53 pages 3-5)
Key source: Guo et al., Nucleic Acids Research, October 2011, DOI: https://doi.org/10.1093/nar/gkq983. Human-cell depletion and recruitment experiments showed that loss of E2F1 or GCN5 impaired damage-associated H3K9 acetylation, repair-factor recruitment, and NER efficiency. (guo2011gcn5ande2f1 pages 2-2)
At double-strand breaks, E2F1 and pRB are mutually supportive repair factors. E2F1 recruits p300/CBP, promotes H3K18/H3K56 acetylation, and cooperates with RB and BRG1 to remodel flanking chromatin. This facilitates loading or retention of the MRE11–RAD50–NBS1 complex, RPA, and RAD51, thereby supporting end resection and homologous recombination. E2F1 is consequently an accessory organizer, not a nuclease, ligase, helicase, or repair enzyme. (zhou2023expandingrolesof pages 14-16, manickavinayaham2020thee2f1transcription pages 3-5, manickavinayaham2020thee2f1transcription pages 1-3)
Acetylation-deficient E2F1 knock-in models lose p300/CBP recruitment and downstream chromatin/repair-factor accumulation and show hypersensitivity to ionizing radiation. These physiological results are strong, although the whole-animal evidence comes from mouse models rather than human intervention studies. Manickavinayaham et al., Nature Communications, October 2019, DOI: https://doi.org/10.1038/s41467-019-12861-8; review synthesis published 13 August 2020, DOI: https://doi.org/10.1080/15384101.2020.1801190. (manickavinayaham2020thee2f1transcription pages 3-5, manickavinayaham2020thee2f1transcription pages 1-3)
E2F1 is biologically bifunctional. Physiological activation promotes proliferation, but excessive E2F caused by RB loss can activate ARF, which inhibits MDM2, stabilizes p53, and triggers arrest, senescence, or apoptosis. E2F1 also engages p53-independent death or arrest genes, including TP73, BIM, RASSF1, PPP1R13B, JMY, MOAP1, RBM38, ABTB1, RBBP4, and RBBP7. DP is required for conventional growth-gene activation such as CDC6, whereas ARF activation can show different DP dependence, illustrating that oncogenic-stress signaling is not merely an amplified version of the G1/S program. (zhou2023expandingrolesof pages 14-16, zhou2023expandingrolesof pages 1-2)
ATM/NBS1 signaling also contributes to E2F1-induced p53 and CHK2 phosphorylation and apoptosis. Importantly, this death response can be uncoupled from E2F1-driven DNA synthesis and conventional target-gene activation, reinforcing the view that E2F1 output depends on interacting pathways and post-translational state. (zhou2023expandingrolesof pages 14-16)
The 2023 expert review by Zhou et al. interprets E2F as a central bridge between RB and p53 tumor-suppressor pathways: RB loss releases proliferative E2F activity, but the same deregulation creates an ARF–p53 safeguard. Cancer progression commonly requires evasion of both arms. Published 11 December 2023 in Biology, DOI: https://doi.org/10.3390/biology12121511. (zhou2023expandingrolesof pages 36-37, zhou2023expandingrolesof pages 1-2)
A 2024 PNAS study identified a degradation mechanism in which phosphorylation of E2F1 at Ser403 promotes recognition by the tumor-suppressive ubiquitin-ligase subunit FBXW7, resulting in ubiquitination and proteasomal turnover. The S403A mutant was more stable than wild-type E2F1 in HEK293T cycloheximide-chase experiments. Conversely, Ca²⁺-dependent calcineurin dephosphorylates this site, suppresses FBXW7 binding, and stabilizes E2F1. (sato2024calcineurinmediateddephosphorylationstabilizes pages 11-12, sato2024calcineurinmediateddephosphorylationstabilizes pages 3-4)
Pharmacologically, ionomycin increased E2F1 abundance in MCF7 cells, whereas verapamil reduced E2F1 and produced G1 arrest. In an HT29 colorectal-cancer xenograft model, daily intraperitoneal FK506 was started at an approximate tumor volume of 150 mm³; tumors were significantly smaller than controls from treatment day 12, and E2F1 protein was lower after 21 days. Exact cohort sizes, effect magnitudes, and P values were not available in the retrieved text, so the result should be regarded as promising but incompletely quantified preclinical evidence. Sato et al., October 2024, DOI: https://doi.org/10.1073/pnas.2414618121. (sato2024calcineurinmediateddephosphorylationstabilizes pages 11-12)
A 2024 multi-omics study connected MET receptor signaling to E2F1-dependent de novo purine synthesis. Tepotinib-mediated MET inhibition reduced E2F1 and purine-synthesis enzymes, depleted dNTPs, and increased γH2AX-associated damage in MET-dependent cells and xenografts; transient E2F1 overexpression prevented dNTP depletion and the associated DNA damage. This positions E2F1 as a transcriptional coupling node between growth-factor signaling, nucleotide supply, and DNA integrity, rather than as a metabolic enzyme itself. Turan et al., Cancer Research Communications, July 2024, DOI: https://doi.org/10.1158/2767-9764.CRC-23-0370.
Recent cancer studies also place E2F1 downstream of ERK, MYC–cyclin D–RB, deubiquitinases, and metabolic regulators. However, many such reports are tumor-type-specific regulatory axes and should not be elevated to universal primary functions. The conserved core remains RB-regulated transcription, stress-triggered apoptosis, and chromatin-associated repair.
RB-pathway disruption can release E2F1 and increase proliferation, while high E2F1 may also affect apoptosis, DNA repair, treatment response, and metabolic adaptation. These competing outputs explain why simple E2F1 abundance is not a universally directional prognostic marker. Interpretation requires RB status, TP53/ARF competence, treatment context, and whether E2F1’s proliferative or damage-response program predominates. (zhou2023expandingrolesof pages 14-16, zhou2023expandingrolesof pages 1-2, sato2024calcineurinmediateddephosphorylationstabilizes pages 11-12)
The clinical-trial search retrieved no relevant trial directly targeting E2F1, and the reviewed sources do not establish an approved E2F1-selective drug. Current clinical implementation is therefore indirect:
The 2024 FK506 xenograft result is proof of principle for destabilizing E2F1 indirectly, not validation of systemic calcineurin inhibition as an E2F1-specific cancer therapy. Calcineurin has broad physiological and immune functions, creating substantial selectivity and safety concerns. (sato2024calcineurinmediateddephosphorylationstabilizes pages 11-12, sato2024calcineurinmediateddephosphorylationstabilizes pages 3-4)
Open Targets reports computational/functional associations between E2F1 and neurodegenerative phenotypes, lysosomal-storage disease, and benign prostatic hyperplasia, but the scores are modest and supported by small evidence sets—typically five records per listed association. These database associations should be treated as hypothesis-generating, not equivalent to established causal disease mechanisms or clinical indications. (OpenTargets Search: -E2F1)
Recommended primary annotation:
E2F1 is a predominantly nuclear, sequence-specific E2F/DP-family transcriptional activator that couples cyclin–CDK-mediated pRB inactivation to expression of genes required for G1/S entry, DNA replication, and nucleotide supply. When deregulated or stress modified, it can engage ARF–p53 and p53-independent apoptosis. Independently of transcription, phosphorylated and acetylated E2F1 localizes to damaged chromatin and recruits histone acetyltransferases, remodelers, and nucleotide-excision/homologous-recombination machinery.
Confidence by component:
References
(OpenTargets Search: -E2F1): Open Targets Query (-E2F1, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(zhou2023expandingrolesof pages 2-4): Yaxuan Zhou, Rinka Nakajima, Mashiro Shirasawa, Mariana Fikriyanti, Lin Zhao, Ritsuko Iwanaga, Andrew P. Bradford, Kenta Kurayoshi, Keigo Araki, and Kiyoshi Ohtani. Expanding roles of the e2f-rb-p53 pathway in tumor suppression. Biology, 12:1511, Dec 2023. URL: https://doi.org/10.3390/biology12121511, doi:10.3390/biology12121511. This article has 61 citations.
(zhou2023expandingrolesof pages 14-16): Yaxuan Zhou, Rinka Nakajima, Mashiro Shirasawa, Mariana Fikriyanti, Lin Zhao, Ritsuko Iwanaga, Andrew P. Bradford, Kenta Kurayoshi, Keigo Araki, and Kiyoshi Ohtani. Expanding roles of the e2f-rb-p53 pathway in tumor suppression. Biology, 12:1511, Dec 2023. URL: https://doi.org/10.3390/biology12121511, doi:10.3390/biology12121511. This article has 61 citations.
(manickavinayaham2020thee2f1transcription pages 3-5): Swarnalatha Manickavinayaham, Renier Velez-Cruz, Anup K. Biswas, Jie Chen, Ruifeng Guo, and David G. Johnson. The e2f1 transcription factor and rb tumor suppressor moonlight as dna repair factors. Cell Cycle, 19:2260-2269, Aug 2020. URL: https://doi.org/10.1080/15384101.2020.1801190, doi:10.1080/15384101.2020.1801190. This article has 60 citations and is from a peer-reviewed journal.
(saad2021structuraldeterminantsof pages 25-28): D Saad. Structural determinants of nf-y interaction with partner transcription factors on dna. Unknown journal, 2021.
(rubin2005structureofthe pages 1-2): Seth M. Rubin, Anne-Laure Gall, Ning Zheng, and Nikola P. Pavletich. Structure of the rb c-terminal domain bound to e2f1-dp1: a mechanism for phosphorylation-induced e2f release. Cell, 123:1093-1106, Dec 2005. URL: https://doi.org/10.1016/j.cell.2005.09.044, doi:10.1016/j.cell.2005.09.044. This article has 351 citations and is from a highest quality peer-reviewed journal.
(saad2021highconformationalflexibility pages 8-11): Dana Saad, Cristina Paissoni, Antonio Chaves-Sanjuan, Marco Nardini, Roberto Mantovani, Nerina Gnesutta, and Carlo Camilloni. High conformational flexibility of the e2f1/dp1/dna complex. Sep 2021. URL: https://doi.org/10.1016/j.jmb.2021.167119, doi:10.1016/j.jmb.2021.167119. This article has 9 citations and is from a domain leading peer-reviewed journal.
(saad2021highconformationalflexibility pages 11-13): Dana Saad, Cristina Paissoni, Antonio Chaves-Sanjuan, Marco Nardini, Roberto Mantovani, Nerina Gnesutta, and Carlo Camilloni. High conformational flexibility of the e2f1/dp1/dna complex. Sep 2021. URL: https://doi.org/10.1016/j.jmb.2021.167119, doi:10.1016/j.jmb.2021.167119. This article has 9 citations and is from a domain leading peer-reviewed journal.
(zhou2023expandingrolesof pages 1-2): Yaxuan Zhou, Rinka Nakajima, Mashiro Shirasawa, Mariana Fikriyanti, Lin Zhao, Ritsuko Iwanaga, Andrew P. Bradford, Kenta Kurayoshi, Keigo Araki, and Kiyoshi Ohtani. Expanding roles of the e2f-rb-p53 pathway in tumor suppression. Biology, 12:1511, Dec 2023. URL: https://doi.org/10.3390/biology12121511, doi:10.3390/biology12121511. This article has 61 citations.
(guo2011gcn5ande2f1 pages 2-2): Ruifeng Guo, Jie Chen, David L. Mitchell, and David G. Johnson. Gcn5 and e2f1 stimulate nucleotide excision repair by promoting h3k9 acetylation at sites of damage. Nucleic Acids Research, 39:1390-1397, Oct 2011. URL: https://doi.org/10.1093/nar/gkq983, doi:10.1093/nar/gkq983. This article has 197 citations and is from a highest quality peer-reviewed journal.
(putzer2013e2f1apoptosiscounterattacked pages 5-6): Brigitte M. Pützer and David Engelmann. E2f1 apoptosis counterattacked: evil strikes back. Trends in molecular medicine, 19 2:89-98, Feb 2013. URL: https://doi.org/10.1016/j.molmed.2012.10.009, doi:10.1016/j.molmed.2012.10.009. This article has 109 citations and is from a domain leading peer-reviewed journal.
(manickavinayaham2020thee2f1transcription pages 1-3): Swarnalatha Manickavinayaham, Renier Velez-Cruz, Anup K. Biswas, Jie Chen, Ruifeng Guo, and David G. Johnson. The e2f1 transcription factor and rb tumor suppressor moonlight as dna repair factors. Cell Cycle, 19:2260-2269, Aug 2020. URL: https://doi.org/10.1080/15384101.2020.1801190, doi:10.1080/15384101.2020.1801190. This article has 60 citations and is from a peer-reviewed journal.
(velezcruz2012e2f1andp53 pages 3-5): Renier Vélez-Cruz and David G. Johnson. E2f1 and p53 transcription factors as accessory factors for nucleotide excision repair. International Journal of Molecular Sciences, 13:13554-13568, Oct 2012. URL: https://doi.org/10.3390/ijms131013554, doi:10.3390/ijms131013554. This article has 24 citations.
(sato2024calcineurinmediateddephosphorylationstabilizes pages 11-12): Yuki Sato, Makoto Habara, Shunsuke Hanaki, Takahiro Masaki, Haruki Tomiyasu, Yosei Miki, Masashi Sakurai, Masahiro Morimoto, Daigo Kobayashi, Tatsuo Miyamoto, and Midori Shimada. Calcineurin-mediated dephosphorylation stabilizes e2f1 protein by suppressing binding of the fbxw7 ubiquitin ligase subunit. Proceedings of the National Academy of Sciences of the United States of America, Oct 2024. URL: https://doi.org/10.1073/pnas.2414618121, doi:10.1073/pnas.2414618121. This article has 5 citations and is from a highest quality peer-reviewed journal.
(sato2024calcineurinmediateddephosphorylationstabilizes pages 3-4): Yuki Sato, Makoto Habara, Shunsuke Hanaki, Takahiro Masaki, Haruki Tomiyasu, Yosei Miki, Masashi Sakurai, Masahiro Morimoto, Daigo Kobayashi, Tatsuo Miyamoto, and Midori Shimada. Calcineurin-mediated dephosphorylation stabilizes e2f1 protein by suppressing binding of the fbxw7 ubiquitin ligase subunit. Proceedings of the National Academy of Sciences of the United States of America, Oct 2024. URL: https://doi.org/10.1073/pnas.2414618121, doi:10.1073/pnas.2414618121. This article has 5 citations and is from a highest quality peer-reviewed journal.
(zhou2023expandingrolesof pages 36-37): Yaxuan Zhou, Rinka Nakajima, Mashiro Shirasawa, Mariana Fikriyanti, Lin Zhao, Ritsuko Iwanaga, Andrew P. Bradford, Kenta Kurayoshi, Keigo Araki, and Kiyoshi Ohtani. Expanding roles of the e2f-rb-p53 pathway in tumor suppression. Biology, 12:1511, Dec 2023. URL: https://doi.org/10.3390/biology12121511, doi:10.3390/biology12121511. This article has 61 citations.
(morgunova2015structuralinsightsinto pages 3-3): Ekaterina Morgunova, Yimeng Yin, Arttu Jolma, Kashyap Dave, Bernhard Schmierer, Alexander Popov, Nadejda Eremina, Lennart Nilsson, and Jussi Taipale. Structural insights into the dna-binding specificity of e2f family transcription factors. Nature Communications, Dec 2015. URL: https://doi.org/10.1038/ncomms10050, doi:10.1038/ncomms10050. This article has 94 citations and is from a highest quality peer-reviewed journal.
(saad2021highconformationalflexibility pages 16-19): Dana Saad, Cristina Paissoni, Antonio Chaves-Sanjuan, Marco Nardini, Roberto Mantovani, Nerina Gnesutta, and Carlo Camilloni. High conformational flexibility of the e2f1/dp1/dna complex. Sep 2021. URL: https://doi.org/10.1016/j.jmb.2021.167119, doi:10.1016/j.jmb.2021.167119. This article has 9 citations and is from a domain leading peer-reviewed journal.
(saad2021highconformationalflexibility pages 24-25): Dana Saad, Cristina Paissoni, Antonio Chaves-Sanjuan, Marco Nardini, Roberto Mantovani, Nerina Gnesutta, and Carlo Camilloni. High conformational flexibility of the e2f1/dp1/dna complex. Sep 2021. URL: https://doi.org/10.1016/j.jmb.2021.167119, doi:10.1016/j.jmb.2021.167119. This article has 9 citations and is from a domain leading peer-reviewed journal.